Open AccessRole of bile acid sequestrants in the treatment of type 2 diabetes
Author(s) -
Kohzo Takebayashi,
Yoshimasa Aso,
Toshihiko Iwamoto
Publication year - 2010
Publication title -
world journal of diabetes
Language(s) - English
Resource type - Journals
ISSN - 1948-9358
DOI - 10.4239/wjd.v1.i5.146
Subject(s) - medicine , tolerability , bile acid , cholestyramine , type 2 diabetes , pharmacology , combination therapy , ezetimibe , diabetes mellitus , cholesterol , endocrinology , adverse effect
Cholestyramine is a first-generation bile acid sequestrant (BAS) and antihyperlipidemic agent that currently has limited use because of its relatively weak effect on lowering low density-lipoprotein (LDL)-cholesterol (C) and poor tolerability. The current first choice drugs for hyper-LDL-cholesterolemia are 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) because of their strong LDL-C lowering effects and efficacy in prevention of cardiovascular disease. However, after lowering the target levels of LDL-C in very high risk patients, combination therapy with statins and other antihyperlipidemic drugs may become more important for treatment of hyper-LDL-cholesterolemia. Second-generation BASs such as colesevelam and colestimide have a glucose-lowering effect and improved tolerance, which has led to re-evaluation of their utility in combination with statins or antidiabetic agents.